Assessing Women's Preferences for Postpartum Thromboprophylaxis: the Prefer-Postpartum Study

Pregnancy Related Clinical Trial

— PREFER-PP  

Official title:

Assessing Women's Preferences for Postpartum Thromboprophylaxis: the Prefer-Postpartum Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05897697
• Other study ID #: UGeneva 2021-01336
• Status: Completed
• Start date: September 24, 2021
• Est. completion date: October 7, 2022

Study information

• Verified date: June 2023
• Source: University Hospital, Geneva
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The preferences of pregnant women for postpartum thromboprophylaxis are largely unknown. The aims of this transversal study are to elicit the preferences of pregnant/postpartum women about postpartum thromboprophylaxis in semi-structured interviews, and to estimate the utility of the relevant health states (pulmonary embolism, deep vein thrombosis, postpartum hemorrhage, subcutaneous injections). In this second aim, the investigators will also compare the effect of 2 different techniques to estimate utilities (standard gamble vs. time trade-off), using a randomization of these techniques.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 122
• Est. completion date: October 7, 2022
• Est. primary completion date: October 7, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• women

• ongoing pregnancy or within 7 days of delivery

• fluency in French or English

Exclusion Criteria:

• fetal or neonatal death

Related Conditions & MeSH terms

• Pregnancy Related
• Thromboembolism
• Venous Thromboembolism

Intervention

Other:
• Interview
Structured interview

Locations

Country	Name	City	State
France	Justine Hugon-Rodin	Paris
Switzerland	Marc Blondon	Geneve

Sponsors (1)

Lead Sponsor	Collaborator
Marc Blondon

Countries where clinical trial is conducted

France,  Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Preference for postpartum thromboprophylaxis	Risk of postpartum venous thromboembolism at which thromboprophylaxis is preferred	90 days of delivery
Primary	Quality-of-life of pulmonary embolism, deep vein thrombosis, postpartum hemorrhage and subcutaneous injections	Measurements of utilities of pulmonary embolism, deep vein thrombosis, postpartum hemorrhage and subcutaneous injections, by standard gamble and time trade-off methods	90 days of delivery